[Radio] Gene Editing for Individuals and their Families and Family Caregivers
By Gordon Atherley,
Voice America
| 03. 01. 2016
[an interview with CGS's Marcy Darnovsky]
Episode Description
Dr. Marcy Darnovsky is Executive Director of the Center for Genetics and Society, http://www.geneticsandsociety.org/. She describes her career and the Center’s work. She explains human gene editing, the ways it could be used for medical treatment and research, and the pros and cons. She explains germline gene modification and the Center’s position on its benefits and risks. She highlights policies on human germline modification in influential countries and identifies the main differences. She explains why the prospect of human germline modification is so controversial. She says how well she thinks North American would-be parents and family caregivers understand human gene editing and human germline modification, what more she would like to see done to improve understanding of human gene editing and human germline modification, and what more governments should do to improve information flows to parents, would-be parents and family caregivers, researchers, and the medical profession.
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...